See more : Elitegroup Computer Systems Co.,Ltd. (2331.TW) Income Statement Analysis – Financial Results
Complete financial analysis of Kamada Ltd. (KMDA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Kamada Ltd., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Pan Electronics (India) Limited (PANELEC.BO) Income Statement Analysis – Financial Results
- Brijlaxmi Leasing & Finance Limited (BRIJLEAS.BO) Income Statement Analysis – Financial Results
- CHS Inc. (CHSCP) Income Statement Analysis – Financial Results
- MPM Technologies, Inc. (MPML) Income Statement Analysis – Financial Results
- Mincor Resources NL (MCR.AX) Income Statement Analysis – Financial Results
Kamada Ltd. (KMDA)
About Kamada Ltd.
Kamada Ltd. provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers KAMRAB/KEDRAB for prophylaxis of rabies disease; CYTOGAM for prophylaxis of cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplant; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; VARIZIG for post exposure prophylaxis of varicella; and GLASSIA for intravenous AATD. It also provides KamRho (D) IM for prophylaxis of hemolytic disease of newborns; KamRho (D) IV for immune thermobocytopunic purpura; and snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus. In addition, the company distributes BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN for Allergic rhinitis and Urticaria; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for cytomegalovirus virus; RUCONEST for angioedema attacks; heparin sodium injection for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. Further, it offers IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis ; and ELIGARD for prostate cancer. The company markets its products through strategic partners in the United States, as well as through distributors internationally. Kamada Ltd. has strategic partnerships with Takeda Pharmaceuticals Company Limited; PARI GmbH; and Kedrion Biopharma. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 142.52M | 129.34M | 103.64M | 133.25M | 127.19M | 114.47M | 102.83M | 77.49M | 70.11M | 71.93M | 70.62M | 72.68M | 55.92M | 36.27M | 14.98M | 15.21M | 13.44M |
| Cost of Revenue | 87.03M | 82.64M | 73.31M | 85.69M | 77.45M | 73.00M | 70.74M | 55.84M | 54.11M | 56.31M | 44.22M | 49.98M | 40.20M | 30.20M | 15.83M | 15.14M | 10.28M |
| Gross Profit | 55.49M | 46.70M | 30.33M | 47.55M | 49.74M | 41.47M | 32.09M | 21.65M | 16.01M | 15.62M | 26.41M | 22.69M | 15.72M | 6.07M | -847.15K | 70.83K | 3.16M |
| Gross Profit Ratio | 38.94% | 36.11% | 29.26% | 35.69% | 39.11% | 36.23% | 31.21% | 27.94% | 22.83% | 21.72% | 37.39% | 31.23% | 28.11% | 16.74% | -5.66% | 0.47% | 23.52% |
| Research & Development | 13.93M | 13.17M | 11.36M | 13.61M | 13.06M | 9.75M | 11.97M | 16.25M | 16.53M | 16.03M | 12.75M | 11.82M | 11.03M | 9.76M | 0.00 | 12.37M | 0.00 |
| General & Administrative | 18.25M | 12.80M | 12.64M | 10.14M | 9.19M | 8.53M | 8.27M | 7.64M | 7.04M | 7.59M | 7.86M | 4.41M | 4.82M | 4.78M | 13.83M | 4.11M | 16.63M |
| Selling & Marketing | 9.20M | 15.28M | 6.28M | 4.52M | 4.37M | 3.63M | 4.40M | 3.24M | 3.86M | 2.90M | 2.10M | 1.85M | 2.19M | 2.26M | 236.80K | 631.68K | 196.59K |
| SG&A | 27.45M | 28.09M | 18.91M | 14.66M | 13.56M | 12.16M | 12.67M | 10.89M | 10.90M | 10.49M | 9.96M | 6.26M | 7.01M | 7.04M | 14.07M | 4.74M | 16.83M |
| Other Expenses | 4.04M | 912.00K | 753.00K | 49.00K | 330.00K | 997.00K | 649.00K | 712.00K | 524.00K | 455.00K | 444.00K | 373.00K | 0.00 | 0.00 | 749.21K | 0.00 | 1.10M |
| Operating Expenses | 45.43M | 42.17M | 31.02M | 28.32M | 26.95M | 22.21M | 24.64M | 27.13M | 27.43M | 26.52M | 22.71M | 18.46M | 18.04M | 16.81M | 14.82M | 17.11M | 17.93M |
| Cost & Expenses | 132.46M | 124.81M | 104.34M | 114.01M | 104.40M | 95.21M | 95.38M | 82.98M | 81.54M | 82.83M | 66.92M | 68.44M | 58.24M | 47.01M | 30.65M | 32.26M | 28.21M |
| Interest Income | 588.00K | 91.00K | 295.00K | 1.03M | 1.15M | 820.00K | 500.00K | 469.00K | 463.00K | 1.61M | 289.00K | 578.00K | 2.62M | 589.63K | 116.42K | 85.25K | 216.82K |
| Interest Expense | 1.30M | 914.00K | 1.28M | 266.00K | 293.00K | 340.00K | 162.00K | 126.00K | 934.00K | 3.09M | 3.15M | 3.36M | 3.79M | 5.03M | 4.04M | 4.60M | 442.71K |
| Depreciation & Amortization | 11.47M | 11.61M | 5.83M | 5.25M | 4.66M | 3.56M | 3.65M | 3.36M | 3.23M | 2.79M | 3.00M | 3.04M | 2.86M | 2.78M | 2.47M | 2.37M | 2.13M |
| EBITDA | 21.53M | 4.53M | 5.20M | 25.41M | 27.30M | 23.46M | 11.25M | -1.98M | -7.10M | -8.31M | 8.09M | 7.18M | 2.72M | -9.38M | -15.52M | -14.67M | -20.33M |
| EBITDA Ratio | 15.11% | 8.13% | 5.02% | 18.88% | 22.37% | 20.78% | 11.15% | -1.95% | -11.03% | -9.04% | 9.90% | 10.81% | 5.64% | -21.93% | -87.98% | -96.45% | -93.31% |
| Operating Income | 10.06M | -1.64M | -401.00K | 19.24M | 22.78M | 19.26M | 7.44M | -5.84M | -11.42M | -10.90M | 3.70M | 4.24M | -2.32M | -10.73M | -16.37M | -17.04M | -16.32M |
| Operating Income Ratio | 7.06% | -1.27% | -0.39% | 14.44% | 17.91% | 16.82% | 7.24% | -7.54% | -16.29% | -15.16% | 5.24% | 5.83% | -4.14% | -29.59% | -109.31% | -112.02% | -121.42% |
| Total Other Income/Expenses | -1.64M | -6.79M | -1.19M | -672.00K | 197.00K | 1.08M | -274.00K | 470.00K | 154.00K | -1.68M | -3.23M | -3.46M | -1.18M | -4.44M | -5.66M | 4.60M | -6.58M |
| Income Before Tax | 8.43M | -2.26M | -1.89M | 18.57M | 22.98M | 20.34M | 7.17M | -5.01M | -11.27M | -12.58M | 467.00K | 783.00K | -3.49M | -15.17M | -22.03M | -12.45M | -22.90M |
| Income Before Tax Ratio | 5.91% | -1.75% | -1.82% | 13.93% | 18.07% | 17.77% | 6.97% | -6.47% | -16.07% | -17.49% | 0.66% | 1.08% | -6.25% | -41.83% | -147.09% | -81.81% | -170.39% |
| Income Tax Expense | 145.00K | 62.00K | 345.00K | 1.43M | 730.00K | -1.96M | 269.00K | 1.72M | -154.00K | 52.00K | 24.00K | 523.00K | 3.79M | 4.44M | 5.66M | -4.60M | 8.13M |
| Net Income | 8.28M | -2.32M | -2.23M | 17.14M | 22.25M | 22.30M | 6.90M | -6.73M | -11.27M | -12.64M | 443.00K | 260.00K | -3.49M | -15.17M | -22.03M | -12.45M | -22.90M |
| Net Income Ratio | 5.81% | -1.79% | -2.15% | 12.86% | 17.49% | 19.48% | 6.71% | -8.69% | -16.07% | -17.57% | 0.63% | 0.36% | -6.25% | -41.83% | -147.09% | -81.81% | -170.39% |
| EPS | 0.17 | -0.05 | -0.05 | 0.42 | 0.57 | 0.55 | 0.18 | -0.18 | -0.31 | -0.35 | 0.01 | 0.01 | -0.13 | -0.61 | -0.88 | -0.94 | -2.16 |
| EPS Diluted | 0.15 | -0.05 | -0.05 | 0.41 | 0.57 | 0.55 | 0.18 | -0.18 | -0.31 | -0.35 | 0.01 | 0.01 | -0.13 | -0.61 | -0.88 | -0.94 | -2.16 |
| Weighted Avg Shares Out | 48.83M | 44.82M | 44.77M | 44.14M | 40.32M | 40.28M | 37.97M | 36.42M | 36.25M | 35.71M | 32.71M | 28.08M | 27.55M | 25.06M | 25.06M | 13.20M | 10.61M |
| Weighted Avg Shares Out (Dil) | 53.68M | 44.82M | 44.77M | 44.59M | 40.58M | 40.54M | 38.05M | 36.43M | 36.25M | 35.97M | 33.39M | 28.69M | 27.70M | 25.06M | 25.06M | 13.20M | 10.61M |
Kamada Ltd. (KMDA) CEO Amir London on Q3 2020 Results - Earnings Call Transcript
Kamada: Q3 Earnings Insights
Kamada to Announce Third Quarter Ended September 30, 2020 Financial Results and Host Conference Call on November 11, 2020
Kamada Looks Cheap AS Takeda Deal Creates Value
Kamada Announces Supply Agreement with Israeli Ministry of Health for its Investigational IgG Product for COVID-19; Initial Order Expected to Generate $3.4 Million in Revenue in First Quarter of 2021
Kamada Provides Update on 2021 GLASSIA® Supply to Takeda
Kamada Announces Completion of Enrollment and Initial Interim Results from its Phase 1/2 Clinical Trial in Israel of its Plasma-Derived Hyperimmune Immunoglobulin (IgG) Product as a Potential Treatment for Coronavirus Disease (COVID-19)
Kamada and Kedrion Biopharma Announce Results of First and Only U.S. Post-Marketing Pediatric Trial of a Human Rabies Immune Globulin (HRIG); The Study Met Its Primary Objective
Kamada Announces Changes to its Board of Directors
Kamada Reports Second Quarter and First Six Months of 2020 Financial Results, Recent Corporate Achievements and Strong Cash Position
Source: https://incomestatements.info
Category: Stock Reports